| CAI | cellular adaptive immunotherapy; complete androgen insensitivity; computer-assisted instruction |
|---|---|
| CAIS | complete androgen insensitivity syndrome |
| FAI | first aid instruction; free androgen index; functional aerobic impairment; functional assessment inv... |
| PAIS | partial androgen insensitivity syndrome; phosphoribosylaminoimidazole synthetase; psychosocial adjus... |
| CBG | capillary blood gases; coronary bypass graft; corticosteroid-binding globulin; cortisol-binding glob... |
| DNA-binding proteins | Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. (12 Dec 1998) |
|---|---|
| insulin binding | When insulin attaches itself to something else. This can occur in two ways. First, when a cell needs energy, insulin can bind with the outer part of the cell. The cell then can bring glucose (sugar) inside and use it for energy. With the help of insulin, the cell can do its work very well and very quickly. But sometimes the body acts against itself. In this second case, the insulin binds with antibodies. If the insulin is an injected form of insulin and not made by the body, the body sees the insulin as an outside or foreign substance. When the injected insulin binds with the antibodies, it does not work as well as when it binds directly to the cell. (09 Oct 1997) |
| insulin-like growth-factor-binding proteins | A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (int j gynaecol obstet 1992;39(1):3-9) (12 Dec 1998) |
| iron-binding capacity | The capacity of iron-binding protein in serum (transferrin) to bind serum iron. (05 Mar 2000) |
| testosterone-oestrogen-binding globulin | A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Changes in its concentration significantly affect the ratio of unbound (biologically active) testosterone to estradiol in plasma. (12 Dec 1998) |
| thyroid binding globulin | <protein> Thyroid binding globulin (TBG) is a plasma protein which binds the majority of thyroid hormone in the bloodstream. Bound thyroid hormone is inactive, only the unbound fraction (0.3%) is considered active. Birth control pills and pregnancy can lead to increased TBG levels in the plasma. Androgens can decrease TBG levels in the plasma. (27 Sep 1997) |
| thyroxine-binding globulin | An alpha-globulin of blood with a strong binding affinity for thyroxine; triiodothyronine is bound to it much less firmly; a deficiency or excess of this protein may occur as a rare benign X-linked disorder. Synonym: thyroxine-binding protein. (05 Mar 2000) |
| thyroxine-binding proteins | A group of proteins that includes thyroxine-binding globulin, a glycoprotein that serves as the major and specific carrier of thyroxine in plasma, accounting for 70-75% of the bound thyroxine; thyroxine-binding prealbumin, an albumin that serves as the secondary carrier, accounting for between 20 and 25% of the bound thyroxine; and serum albumin, which accounts for the remaining bound thyroxine. (12 Dec 1998) |
| total iron binding capacity | <biochemistry, haematology> A test that measures indirectly the transferrin level in the bloodstream. Transferrin is a protein that carries iron in the body. Normal values are 240 to 450 mcg/dl. This test is used to evaluate anaemia. Greater than normal total iron binding capacity can be seen in: iron deficiency anaemia, late pregnancy and polycythaemia vera. Lower than normal total iron binding capacity can be seen in cirrhosis, sickle cell anaemia, hypoproteinaemia, pernicious anaemia and haemolytic anaemia. The use of birth control pills can lead to increased total iron binding capacity measurements. Acronym: TIBC (12 Jan 1998) |
| fatty acid binding proteins | <biochemistry> Group of small cytosolic proteins that bind fatty acids or other organic solutes. (18 Nov 1997) |
| zero time-binding DNA | DNA that has become the duplex form at the start of a reassociation process. Acronym: DNA (05 Mar 2000) |
| ligand binding site | The site on a protein's surface that binds a ligand; equivalent to the active site if the ligand is the substrate of an enzyme. (05 Mar 2000) |
| acetoacetyl-acyl carrier protein synthase | <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin Registry number: EC 2.3.1.- Synonym: acetoacetyl-acp synthase (26 Jun 1999) |
| acid soluble spore protein | <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light. (18 Nov 1997) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |